VAISHALI — Vaishali Pharma Share Price
- IN₹1.89bn
- IN₹1.89bn
- IN₹862.80m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.29 | ||
Price to Tang. Book | 4.37 | ||
Price to Free Cashflow | 264.13 | ||
Price to Sales | 2.13 | ||
EV to EBITDA | 161.32 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 1.34% | ||
Return on Equity | 1.72% | ||
Operating Margin | 0.73% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 600.86 | 537.74 | 758.21 | 696.63 | 862.8 | n/a | n/a | 2.82% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -95.4 | +3090.96 | +284.57 | +54.92 | -89.17 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The Company markets approximately 1,500 products and has more than 200 brands, around 35 countries.
Directors
- Atul Vasani CHM (52)
- Hemanth Pathak CEO
- Ratnesh Singh CFO (39)
- Akshay Jharkhandi CCO
- Jagruti Vasani EDR (54)
- Dewansh Vasani NED (25)
- Ashvin Ganatra NID (51)
- Prataprai Gandhi NID (78)
- Manish Ved NID (54)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- April 25th, 2008
- Public Since
- August 22nd, 2017
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 11,144,213
- Address
- 706-709, Aravalli Business Center R.C.Pa, MUMBAI, 400092
- Web
- https://www.vaishalipharma.com/
- Phone
- +91 2242171819
- Auditors
- Raman S Shah & Associates
Upcoming Events for VAISHALI
Vaishali Pharma Ltd Annual Shareholders Meeting
Q2 2025 Vaishali Pharma Ltd Earnings Release
Similar to VAISHALI
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 17:59 UTC, shares in Vaishali Pharma are trading at IN₹164.89. This share price information is delayed by 15 minutes.
Shares in Vaishali Pharma last closed at IN₹164.89 and the price had moved by +30.61% over the past 365 days. In terms of relative price strength the Vaishali Pharma share price has underperformed the S&P BSE 100 Index by -0.2% over the past year.
There is no consensus recommendation for this security.
Vaishali Pharma does not currently pay a dividend.
Vaishali Pharma does not currently pay a dividend.
Vaishali Pharma does not currently pay a dividend.
To buy shares in Vaishali Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹164.89, shares in Vaishali Pharma had a market capitalisation of IN₹1.84bn.
Here are the trading details for Vaishali Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: VAISHALI
Based on an overall assessment of its quality, value and momentum Vaishali Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaishali Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -18.69%.
As of the last closing price of IN₹164.89, shares in Vaishali Pharma were trading +8.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vaishali Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹164.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vaishali Pharma's management team is headed by:
- Atul Vasani - CHM
- Hemanth Pathak - CEO
- Ratnesh Singh - CFO
- Akshay Jharkhandi - CCO
- Jagruti Vasani - EDR
- Dewansh Vasani - NED
- Ashvin Ganatra - NID
- Prataprai Gandhi - NID
- Manish Ved - NID